STC-Technology – Maquette Brenus

AN INNOVATION TO MIMIC PATIENT'S RELAPSING CONDITIONS

EDUCATING IMMUNE SYSTEM TO ANTICIPATE RELAPSE MECHANISMS

aQualitative cancer-related proteins overexpressed.

By stimulation of selected tumor cell lines with standards of care used in the targeted indication.

RT: MUC1 (CRC)

Mucine; Cell Surface Associated – Overexpression associated with carcinomas

RT: MDR1 (CRC)

ATP efflux pump – Therapeutic resistance

TP: EPCAM

Marker for carcinoma – Fast growing epithelial tumors

RT: ABCC1

ABC transporter – Multiple Therapeutics resistance

TS: ICAM1 (CRC)

Widely expressed in tumor cells – Tumor progression

… 100+ Validated by multi-omics analysis.

ENSURING IMMUNE SYSTEM ACTIVATION

bHaptenization: boosting antigen's immune recognition.

cAllogeneic tumor ghost cells

FIRST-IN-CLASS TUMOR ANTIGEN-FOCUSED IMMUNOTHERAPY

Anticipating tumor plasticity from early stage to relapsing disease.

STC TECHNOLOGY EDUCATES IMMUNE SYSTEM TO RECOGNIZE AND ANTICIPATE ESCAPE MECHANISMS IN COLD TUMOR.

What happens in vivo after ID injection ?

Step 1

APC* Cross priming activation

Petient's Dentritic Cells maturation with no HLA restriction.
(*Antigen-Presenting Cell ; Dentritic Cells)

Step 2

TILs education

TILs (Tumor-Inflitrating Lymphocytes) pool generation multispecific of resistance factors: TAA/TSA.
(TAA = Tumor Associated Antigens & TSA = Tumor Specific Antigens)

Step 3

TILs expansion

The Multi specific TILs Pool generated expands, ready for TSA/TAA recognition.

Step 4

Patient's resistance tumor cells' destruction

TILs synergize on multiple qualitative targets and enhance immune modulators repsonse in combination.

A LIMITLESS POTENTIAL TO GENERATE FIRST-IN-CLASS IMMUNOTHERAPIES

Cell lines selection from tumor banks :

PROVIDING A UNIQUE
VALUE PROPOSAL IN THE FIELD

Ready to use, standardized & scalable

Defined biological raw material (cell banks)
GLP/GMP Pharmaceutical development & Pre scale-up validated

FDA PRE IND & FAMHP (EMA) Scientific advises passed

Quick generation of First-In-Class Therapies

Patented platform, protected in key countries

Limitless potential to generate a strong pipeline

LEVERAGING OUR PLATFORM TO GENERATE STRONG CANDIDATES.

INTERESTED
IN OUR TECHNOLOGY ?

STAY TUNED

NEWS

Press Release

3 February 2024

Brenus annouces its international scientific committee.

Scientific results

3 February 2024

ASCO annual meeting 2023 (HCL, Inovotion, Explicyte, IRCM, CGFL)

Scientific results

3 February 2024

Poster AACR Annual meeting 2023 (Explicyte, Institut Bergonié)

Scientific results

3 February 2024

Poster AACR Annual meeting 2023 (Inovotion)

Scientific results

3 February 2024

Poster SITC Annual Meeting 2022 (CLB, IRCM)

Scientific results

3 February 2024